In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $484.01, marking a +0.11% move from the previous day. This change outpaced the S&P 500's 4.84% loss on the day. At the same time, ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best ...

RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

The equity portion of the Abrdn Healthcare Investors Fund fell (gross of fees) but outperformed its custom benchmark over the ...